Janux Therapeutics (JANX) Common Equity (2020 - 2026)

Janux Therapeutics (JANX) has reported Common Equity for 7 consecutive years, with $941.5 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Common Equity fell 7.01% year-over-year to $941.5 million; the TTM figure through Mar 2026 stood at $941.5 million (down 7.01% YoY), while the FY2025 annual figure was $956.8 million, down 6.45% from the prior year.
• Common Equity eased to $941.5 million in Q1 2026 per JANX's latest filing, from $956.8 million in the prior quarter.
• Across five years, Common Equity topped out at $1.0 billion in Q4 2024 and bottomed at $299.5 million in Q2 2023.
• Historically, Common Equity has averaged $619.2 million across 5 years, with a median of $655.8 million in 2024.
• Annual changes were most pronounced in 2022 — Common Equity soared 2223.2% — and 2023, when it slipped 12.9%.
• Janux Therapeutics' Common Equity stood at $320.7 million in 2022, then rose by 7.36% to $344.3 million in 2023, then soared by 197.02% to $1.0 billion in 2024, then dropped by 6.45% to $956.8 million in 2025, then declined by 1.6% to $941.5 million in 2026.
• Business Quant data shows JANX's Common Equity at $941.5 million in Q1 2026, $956.8 million in Q4 2025, and $976.6 million in Q3 2025.